Results & Financial lifeHealthcare - Pharma - Biotech
Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
09/11/2026 17:45
AMFImmediate publication
Publication in Nature Communications confirmed TG4050’s robust clinical proof of principle, with 100% DFS sustained after more than 3 years of follow-up in head and neck cancer (HNSCC)
Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
Publication in Nature Communications confirmed TG4050’s robust clinical proof of principle, with 100% DFS sustained after more than 3 years of follow-up in head and neck cancer (HNSCC)
Expansion of the myvac® platform with the initiation of the Phase 1 clinical trial of
TG4070 in lung cancer (NSCLC)
Clear strategic and clinical development plan in early-stage solid tumors with financial visibility confirmed through early 2028
Strasbourg, France, November 9, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company developing myvac®, an individualized neoantigen therapeutic vaccines (INTV) platform designed to prevent cancer recurrence, alongside a portfolio of viral vector-based candidates, today provides a business update on its myvac®-based individualized assets
TG4050 and TG4070, its upcoming plans, and its financial position as of September 30, 2026.
TG4050: 100% DFS sustained after more than 3 years of follow-up
Strong Phase 1 data from the randomized Phase 1/2 trial (NCT04183166), demonstrating the potential of TG4050 to prevent recurrence in patients early-stage HNSCC at high risk of relapse following surgery and (chemo)-radiotherapy, have been published in Nature Communications (see press release). TG4050 showed a favorable safety profile and induced persistent neoantigenspecific T cell responses, with a 100% disease-free survival (DFS) rate sustained after more than three years of follow-up.
The Phase 2 part of the study is ongoing. First immunological data are expected by year end, with the aim of presenting them at a scientific conference in 2027. Transgene expects to communicate topline results from TG4050’s Phase 2 trial by the end of Q1 2028.
In parallel, Transgene continues to strengthen its manufacturing capabilities in preparation for a potential Phase 3 trial in HNSCC. This includes transitioning TG4050 into a scalable cell linebased manufacturing process.
The Company remains on track to have Phase 3-ready manufacturing capacity by the end of 2027.
P R E S S R E L E A S E
TG4070: all French clinical sites open, enabling patient recruitment to begin
TG4070, Transgene’s second Individualized Neoantigen Therapeutic Vaccine (INTV) candidate, represents an important strategic expansion of the myvac® platform.
Combining Transgene’s own cutting-edge proprietary AI-driven technologies for neoantigen selection with scalable manufacturing capabilities, TG4070 is designed to broaden the application of individualized cancer vaccines across multiple solid tumor indications, at an early stage of the disease.